(secondQuint)The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer.

 1200 patients with stage IV colorectal cancer,who had received surgery and chemotherapy,will be randomly divided into group A(receive CIK plus S-1 and Bevacizumab ) or group B(just receive S-1 and Bevacizumab),and the randomize ratio will be 1:1.

 Patients in group A will receive 3 cycles of CIK treatment (every 1 year) and Apatinib (continuous).

Patients in group B will receive only S-1 and Bevacizumab (continuous) .

.

 The Study of CIK Plus S-1 and Bevacizumab as Maintenance Treatment for Patients With Advanced Colorectal Cancer@highlight

The purpose of this study is to evaluate the safety and efficacy of cytokine-induced killer cell (CIK) plus S-1 and Bevacizumab vs S-1 and Bevacizumab as Maintenance Treatment for patients with advanced colorectal cancer.

